Your browser doesn't support javascript.
loading
[Clinical Characteristics and Long-term Prognosis Analysis of Patients with Primary Bone Lymphoma].
Zhong, Kai-Li; Cao, Bao-Ping; Guo, Xiao-Chuan; Huang, Le-Fu; Wang, Wei-Xia; Wang, Bin; Zhang, Wei-Jing.
Afiliación
  • Zhong KL; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
  • Cao BP; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
  • Guo XC; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
  • Huang LF; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
  • Wang WX; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
  • Wang B; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
  • Zhang WJ; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China,E-mail: zhangweijing7132@bjsjth.cn.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 30(1): 126-130, 2022 Feb.
Article en Zh | MEDLINE | ID: mdl-35123614
OBJECTIVE: To analyze the clinical characteristics and long-term prognosis of patients with primary bone lymphoma (PBL). METHODS: The clinical data of 21 patients with PBL treated in our center from 2005 to 2018 were analyzed retrospectively, the clinical characteristics and the factors affecting prognosis of the patients were analyzed. RESULTS: The median age of all the 21 newly diagnosed PBL patients was 40(12-71) years old. Ostealgia was the initial symptom in most of the patients (19/21,90.5%). 42.9%(9/21) of the patients showed single bone lesion only. 571% (12/21) of the patients showed diffuse large B cell lymphoma. 28.6% (6/21) of the patients showed anaplastic large cell lymphoma and 9.5% (2/21) of the patients showed T cell lymphoblastic lymphoma. All the patients received chemotherapy (CHOP or CHOP like regimen, 33.3% plus rituximab) with or without radiotherapy and/or autologous hematopoietic stem cell transplantation (ASCT). 18 patients achieved clinical remission (including 15 for CR and 3 for PR). The median follow-up time was 48 months. The 5-year overall survival rate and progression-free survival rate of the patients were was 67.5% and 63.7%, respectively. The single factors analysis showed that ASCT was the important prognostic factor of PFS, while the single or multiple bone lesion was the factors affecting OS of the patients. There were no statistical differences with the effects of age, sex, stage, ECOG score, LDH level, B symptoms and radiotherapy for the prognosis of patients. CONCLUSION: Diffuse large B cell lymphoma is the most common pathological type of PBL. Chemotherapy is the main treatment, which can be combined with radiotherapy and/or ASCT. The ASCT and the number of bone lesion are the factors for long time survival of the patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Humans / Middle aged Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Humans / Middle aged Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: China